LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

Kodu・Aktsiate loetelu・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Suletud

SektorTervishoid

20.05 -1.04

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.85

Max

20.5

Põhinäitajad
By Trading Economics
Sissetulek	-4.6M 52M
Müük	5.1M 147M
P/E Sektori keskmine	12.479 35.733
Kasumimarginaal	35.553
Töötajad	181
EBITDA	5.9M 79M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+62.64% upside

Turustatistika
By TradingEconomics
Turukapital	-130M 2.5B
Eelmine avamishind	21.09
Eelmine sulgemishind	20.05

Uudiste sentiment

By Acuity

40%

60%

147 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

N/A / 24.28 Toetus ja vastupanu

Catalyst Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. sept 2025, 23:59 UTC

Omandamised, ülevõtmised, äriostud

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8. sept 2025, 22:02 UTC

Suurimad hinnamuutused turgudel

Microsoft Signs $17.4 Billion AI Deal With Nebius

8. sept 2025, 17:01 UTC

Suurimad hinnamuutused turgudel

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8. sept 2025, 17:01 UTC

Suurimad hinnamuutused turgudel

Tron Shares Rise After New Investment From Bravemorning

8. sept 2025, 16:14 UTC

Suurimad hinnamuutused turgudel

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8. sept 2025, 16:13 UTC

Suurimad hinnamuutused turgudel

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8. sept 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. sept 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8. sept 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8. sept 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8. sept 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8. sept 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8. sept 2025, 21:47 UTC

Suurimad hinnamuutused turgudel

Microsoft Signs $17.4B AI Deal With Nebius

8. sept 2025, 21:33 UTC

Omandamised, ülevõtmised, äriostud

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8. sept 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8. sept 2025, 21:19 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8. sept 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8. sept 2025, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

8. sept 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8. sept 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8. sept 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8. sept 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. sept 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8. sept 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8. sept 2025, 16:59 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8. sept 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8. sept 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. sept 2025, 16:16 UTC

Tulu

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8. sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. sept 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Catalyst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

62.64% tõus

12 kuu keskmine prognoos

Keskmine 33 USD 62.64%

Kõrge 35 USD

Madal 31 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Catalyst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Catalyst Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 24.28Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

147 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.